{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:44:54Z","timestamp":1774266294454,"version":"3.50.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.reuma.2015.06.002","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T21:41:01Z","timestamp":1438897261000},"page":"39-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rituximab como terapia de mantenimiento en las vasculitis asociadas a ANCA: \u00bfc\u00f3mo, cu\u00e1ndo y por qu\u00e9?"],"prefix":"10.1016","volume":"12","author":[{"given":"Marco A.","family":"Alba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Felipe","family":"Flores-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2015.06.002_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2015.06.002_bib0010","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.reuma.2011.10.006","article-title":"Rituximab for the treatment of ANCA associated vasculitis: The future today?","volume":"7","author":"Alba","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reuma.2015.06.002_bib0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.reuma.2014.08.005","article-title":"Rituximab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"11","author":"Munoz","year":"2015","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2015.06.002_bib0020","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial","volume":"150","author":"De Groot","year":"2009","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.reuma.2015.06.002_bib0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reuma.2015.06.002_bib0030","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA."},{"key":"10.1016\/j.reuma.2015.06.002_bib0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reuma.2015.06.002_bib0040","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reuma.2015.06.002_bib0045","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2015.06.002_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/BOR.0000000000000005","article-title":"Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis","volume":"26","author":"Furuta","year":"2014","journal-title":"Curr Opin Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneph.2013.225","article-title":"Treatment of ANCA-associated vasculitis","volume":"10","author":"Schonermarck","year":"2014","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ki.1994.239","article-title":"Anti-neutrophil cytoplasmic antibodies: Current diagnostic and pathophysiological potential","volume":"46","author":"Kallenberg","year":"1994","journal-title":"Kidney Int."},{"key":"10.1016\/j.reuma.2015.06.002_bib0065","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0070","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7326\/0003-4819-120-1-199401010-00003","article-title":"Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis","volume":"120","author":"Stegeman","year":"1994","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.reuma.2015.06.002_bib0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/art.20234","article-title":"Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis","volume":"51","author":"Slot","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0085","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reuma.2015.06.002_bib0090","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0091-6749(99)70434-3","article-title":"Differential B- and T-cell activation in Wegener's granulomatosis","volume":"103","author":"Popa","year":"1999","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0095","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1681\/ASN.2005101048","article-title":"Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies","volume":"17","author":"Jennette","year":"2006","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0100","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest."},{"key":"10.1016\/j.reuma.2015.06.002_bib0105","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/art.10384","article-title":"In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase","volume":"46","author":"Popa","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0110","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/ard.2005.044909","article-title":"B lymphocyte maturation in Wegener's granulomatosis: A comparative analysis of VH genes from endonasal lesions","volume":"65","author":"Voswinkel","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2015.06.002_bib0115","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24454","article-title":"Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis","volume":"60","author":"Taylor","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0120","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1093\/ndt\/gfn318","article-title":"Relapsed Wegener's granulomatosis after rituximab therapy \u2014B cells are present in new pathological lesions despite persistent \u201cdepletion\u201d of peripheral blood","volume":"23","author":"Ferraro","year":"2008","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.reuma.2015.06.002_bib0125","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.4049\/jimmunol.128.6.2453","article-title":"Suppression of human B lymphocyte function by cyclophosphamide","volume":"128","author":"Cupps","year":"1982","journal-title":"J Immunol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0130","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood."},{"key":"10.1016\/j.reuma.2015.06.002_bib0135","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00467-008-1010-z","article-title":"Targeting the B cell in vasculitis","volume":"24","author":"Walsh","year":"2009","journal-title":"Pediatr Nephrol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0140","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0145","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clim.2008.01.011","article-title":"Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells","volume":"127","author":"Liossis","year":"2008","journal-title":"Clin Immunol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2249.2009.03978.x","article-title":"Translational mini-review series on b cell-directed therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases \u2014lessons from B cell-depletion therapy","volume":"157","author":"Leandro","year":"2009","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0155","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reuma.2015.06.002_bib0160","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MD.0000000000000020","article-title":"Granulomatosis with polyangiitis (Wegener's): Impact of maintenance therapy duration","volume":"93","author":"Springer","year":"2014","journal-title":"Medicine (Baltimore)."},{"issue":"Suppl 1","key":"10.1016\/j.reuma.2015.06.002_bib0165","first-page":"S1","article-title":"Rituximab (MabThera) therapy and safety management. Clinical tool guide","volume":"75","author":"Pham","year":"2008","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.reuma.2015.06.002_bib0170","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/03009742.2014.918172","article-title":"Single-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: A retrospective analysis of 17 patients","volume":"43","author":"Moog","year":"2014","journal-title":"Scand J Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0175","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/00365599.2010.504193","article-title":"Rituximab for rescue and maintenance therapy in rapidly progressive life-threatening antineutrophil cytoplasmic autoantibody-associated systemic vasculitis","volume":"44","author":"Jose","year":"2010","journal-title":"Scand J Urol Nephrol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0180","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0185","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0190","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center","volume":"64","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0195","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2215\/CJN.08821209","article-title":"Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"5","author":"Rhee","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0200","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2215\/CJN.07340713","article-title":"Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis","volume":"9","author":"Pendergraft","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3899\/jrheum.110143","article-title":"Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis","volume":"39","author":"Roubaud-Baudron","year":"2012","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0210","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","article-title":"Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: A multicentre retrospective study on 80 patients","volume":"53","author":"Charles","year":"2014","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2015.06.002_bib0215","doi-asserted-by":"crossref","unstructured":"Alberici F, Smith RM, Jones RB, Roberts DM, Willcocks LC, Chaudhry A, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2015;54:1153-60.","DOI":"10.1093\/rheumatology\/keu452"},{"key":"10.1016\/j.reuma.2015.06.002_bib0220","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2014.03.002","article-title":"Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients","volume":"50","author":"Calich","year":"2014","journal-title":"J Autoimmun."},{"key":"10.1016\/j.reuma.2015.06.002_bib0225","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","article-title":"Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre","volume":"52","author":"Besada","year":"2013","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2015.06.002_bib0230","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reuma.2015.06.002_bib0235","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/art.38744","article-title":"Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's): a retrospective single-center study","volume":"66","author":"Azar","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0240","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.lpm.2013.08.003","article-title":"Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides","volume":"42","author":"Charles","year":"2013","journal-title":"Presse Med."},{"key":"10.1016\/j.reuma.2015.06.002_bib0245","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial","volume":"173","author":"Keogh","year":"2006","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.reuma.2015.06.002_bib0250","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0255","doi-asserted-by":"crossref","unstructured":"Guerry MJ, Brogan P, Bruce IN, D\u2019Cruz DP, Harper L, Luqmani R, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51:634-43.","DOI":"10.1093\/rheumatology\/ker150"},{"key":"10.1016\/j.reuma.2015.06.002_bib0260","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/kel098","article-title":"Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab","volume":"45","author":"Stasi","year":"2006","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2015.06.002_bib0265","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/08916934.2014.914174","article-title":"Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease","volume":"47","author":"Venhoff","year":"2014","journal-title":"Autoimmunity."},{"key":"10.1016\/j.reuma.2015.06.002_bib0270","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0275","first-page":"65","article-title":"Long-term effi cacy and safety results of the RAVE trial","volume":"164","author":"Specks","year":"2011","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0280","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","article-title":"Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): Comparison of efficacy in granulomatous versus vasculitic manifestations","volume":"71","author":"Holle","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2015.06.002_bib0285","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000368580","article-title":"Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"128","author":"Jones","year":"2014","journal-title":"Nephron Clin Pract."},{"key":"10.1016\/j.reuma.2015.06.002_bib0290","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/art.22400","article-title":"Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis","volume":"56","author":"Vos","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0295","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0300","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0305","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2215\/CJN.03950412","article-title":"Decreased CD5(+) B cells in active ANCA vasculitis and relapse after rituximab","volume":"8","author":"Bunch","year":"2013","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0310","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.002_bib0315","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/rheumatology\/ker526","article-title":"B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels","volume":"51","author":"Lazarus","year":"2012","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2015.06.002_bib0320","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reuma.2015.06.002_bib0325","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1749-4486.2009.01968.x","article-title":"B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: A cohort study","volume":"34","author":"Martinez del Pero","year":"2009","journal-title":"Clin Otolaryngol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0330","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3899\/jrheum.120482","article-title":"Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: Results from a German registry (GRAID)","volume":"39","author":"Roll","year":"2012","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0335","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-3083.2012.02747.x","article-title":"Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: Long-term follow-up from a single centre","volume":"76","author":"Pullerits","year":"2012","journal-title":"Scand J Immunol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0340","first-page":"2013","article-title":"Rituximab seems to be a safer alternative in patients with active rheumatoid arthritis with tuberculosis","author":"Pehlivan","year":"2013","journal-title":"BMJ case reports"},{"key":"10.1016\/j.reuma.2015.06.002_bib0345","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reuma.2015.06.002_bib0350","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun."},{"key":"10.1016\/j.reuma.2015.06.002_bib0355","doi-asserted-by":"crossref","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","article-title":"Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides","volume":"7","author":"Venhoff","year":"2012","journal-title":"PloS one."},{"key":"10.1016\/j.reuma.2015.06.002_bib0360","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2474-15-178","article-title":"The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease","volume":"15","author":"Marco","year":"2014","journal-title":"BMC Musculoskelet Disord."},{"key":"10.1016\/j.reuma.2015.06.002_bib0365","first-page":"59","article-title":"Hypogammaglobulinaemia and infections following RTX therapy for systemic vasculitis and SLE","volume":"164","author":"Helena","year":"2011","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0370","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.reuma.2015.06.002_bib0375","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10067-013-2351-y","article-title":"Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis-a case series","volume":"33","author":"Knight","year":"2014","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0380","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/ehm.11.62","article-title":"Late-onset neutropenia following rituximab therapy: Incidence, clinical features and possible mechanisms","volume":"4","author":"Tesfa","year":"2011","journal-title":"Expert Rev Hematol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0385","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/acr.20279","article-title":"Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis","volume":"62","author":"Hugle","year":"2010","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"10.1016\/j.reuma.2015.06.002_bib0390","first-page":"90","article-title":"Macular oedema following rituximab infusion in two patients with Wegener's granulomatosis","volume":"28","author":"Bussone","year":"2010","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0395","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/rheumatology\/kem299","article-title":"Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab","volume":"47","author":"Harris","year":"2008","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2015.06.002_bib0400","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/41.7.826","article-title":"Progressive multifocal leucoencephalopathy isolated to the posterior fossa in a patient with systemic lupus erythematosus","volume":"41","author":"White","year":"2002","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2015.06.002_bib0405","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ejh.12102","article-title":"High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia","volume":"90","author":"Gomez-Almaguer","year":"2013","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0410","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2010.01486.x","article-title":"Low-dose rituximab in adult patients with primary immune thrombocytopenia","volume":"85","author":"Zaja","year":"2010","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.reuma.2015.06.002_bib0415","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2215\/CJN.01270214","article-title":"Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis","volume":"9","author":"McAdoo","year":"2014","journal-title":"Clin J Am Soc Nephrol."}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X15001126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X15001126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T22:51:18Z","timestamp":1691880678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X15001126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1699258X15001126"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2015.06.002","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab como terapia de mantenimiento en las vasculitis asociadas a ANCA: \u00bfc\u00f3mo, cu\u00e1ndo y por qu\u00e9?","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2015.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}